Yesterday, Aclaris announced that their oral ATI-501 JAK 1/3 inhibitor Phase 2 clinical trials were successful in treating patients with alopecia areata (AA). No serious side effects reported.
Not a huge surprise since JAK inhibitors have been proven to work well on alopecia areata patients in the past. But a relief after Aclaris’ topical ATI-502 JAK inhibitor failed to treat alopecia areata patients sufficiently well recently.
The latest trial photos are pretty amazing. One of the best ones: